Premium
A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer
Author(s) -
Taira Yusuke,
Shimoji Yuko,
Nakasone Tadaharu,
Arakaki Yoshihisa,
Nakamoto Tomoko,
Kudaka Wataru,
Aoki Yoichi
Publication year - 2021
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.14589
Subject(s) - medicine , bevacizumab , cervical cancer , carboplatin , perforation , ovarian cancer , breast cancer , paclitaxel , surgery , chemotherapy , cancer , cisplatin , materials science , punching , metallurgy
Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48‐year‐old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and paclitaxel and carboplatin along with bevacizumab (triweekly) were administered. After eight courses of chemotherapy, nasal septal perforation was noted. The possibility of nasal septal perforation by bevacizumab was considered by excluding other causes. We report the first case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.